Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss

Articles From: Alvarion® Chosen to Deploy Smart City Solution in Mar del Plata, Argentina for Better Governance, Efficiency of Services and Quality of Life to Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013

This site contains about 63,386 documents.
View by:
Title  |  Date  |  Author  |  Collection  |  Interest  |  Popularity
Page:   1   10   20   30   40   50   60   73   74   75   76   77   78   79   80   81   82   83   84   85   86   87   88   89   90   91   92   93   94   95   96   97   98   99   100   101   102   110   120   130   140   150   160   170   180   200   300   400   500   600   700   800   900   1,000   2,000   2,113 

2013/2/26
Alvarion® Chosen to Deploy Smart City Solution in Mar del Plata, Argentina for Better Governance, Efficiency of Services and Quality of Life
Alvarion ® Ltd.
View more Alvarion® Chosen to Deploy Smart City Solution in Mar del Plata, Argentina for Better Governance, Efficiency of Services and Quality of Life analysis
Sign-up for Alvarion® Chosen to Deploy Smart City Solution in Mar del Plata, Argentina for Better Governance, Efficiency of Services and Quality of Life investment picks
2013/2/20
Alvarion® Postpones Earnings Release Due to Ongoing Negotiations to Sell its Carrier Licensed Business
Alvarion® Ltd.
View more Alvarion® Postpones Earnings Release Due to Ongoing Negotiations to Sell its Carrier Licensed Business analysis
Sign-up for Alvarion® Postpones Earnings Release Due to Ongoing Negotiations to Sell its Carrier Licensed Business investment picks
2013/4/23
AMAG Announces First Quarter 2013 Financial Results
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) , a specialty pharmaceutical company, today reported unaudited consolidated financial results for the quarter ended March 31, 2013.
View more AMAG Announces First Quarter 2013 Financial Results analysis
Sign-up for AMAG Announces First Quarter 2013 Financial Results investment picks
2013/3/1
AMAG Announces Fourth Quarter and Year End 2012 Financial Results
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) , a specialty pharmaceutical company, today reported unaudited consolidated financial results for the fourth quarter and year ended December 31, 2012.
View more AMAG Announces Fourth Quarter and Year End 2012 Financial Results analysis
Sign-up for AMAG Announces Fourth Quarter and Year End 2012 Financial Results investment picks
2013/3/6
AMAG Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Feraheme Label Expansion to Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that the United States Food and Drug Administration (FDA) has accepted for review the company’s supplemental new drug application (sNDA) for Feraheme® (ferumoxytol) Injection for Intravenous (IV) use, which was submitted to the FDA in December 2012.
View more AMAG Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Feraheme Label Expansion to Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron analysis
Sign-up for AMAG Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Feraheme Label Expansion to Include Iron Deficiency Anemia Patients Who Cannot Take Oral Iron investment picks
2013/3/15
AMAG Pharmaceuticals Announces Positive Preliminary Results from an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing with Ferumoxytol in Patients with Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced positive preliminary data from the IDA-303 study.
View more AMAG Pharmaceuticals Announces Positive Preliminary Results from an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing with Ferumoxytol in Patients with Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause analysis
Sign-up for AMAG Pharmaceuticals Announces Positive Preliminary Results from an Extension Study Evaluating the Safety and Efficacy of Repeat Dosing with Ferumoxytol in Patients with Persistent or Recurring Iron Deficiency Anemia, Regardless of the Underlying Cause investment picks
2013/4/26
AMAG Pharmaceuticals to Present at the Needham Healthcare Conference
AMAG Pharmaceuticals, Inc.  (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will present at the Needham Healthcare Conference on Wednesday, May 1, 2013 at 12:50 p.m. Eastern time.
View more AMAG Pharmaceuticals to Present at the Needham Healthcare Conference analysis
Sign-up for AMAG Pharmaceuticals to Present at the Needham Healthcare Conference investment picks
2013/4/19
AMAG Pharmaceuticals, Inc. to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2013 after the U.S. financial markets close on Tuesday, April 23, 2013.
View more AMAG Pharmaceuticals, Inc. to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013 analysis
Sign-up for AMAG Pharmaceuticals, Inc. to Host Conference Call on April 23, 2013 at 4:30 p.m. ET to Discuss Financial Results for the Quarter Ended March 31, 2013 investment picks
2013/2/7
AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will participate in the Leerink Swann Global Healthcare Conference on Wednesday, February 13, 2013 at 2:00 pm Eastern Time.
View more AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference analysis
Sign-up for AMAG Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference investment picks
2013/2/21
AMAG Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, AMAG’s chief executive officer, will participate in the RBC Capital Markets Global Healthcare Conference on Tuesday, February 26, 2013 at 9:30 am ET in New York and the Cowen and Company 33 rd Annual Healthcare Conference on Monday, March 4, 2013 at 2:50 pm ET in Boston.
View more AMAG Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences analysis
Sign-up for AMAG Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences investment picks
2013/4/30
Amanda Knox Opens Up In Exclusive Interview In Today's Editions Of USA TODAY
Knox says "The ideal situation in my mind is that they could show me Meredith's grave.
View more Amanda Knox Opens Up In Exclusive Interview In Today's Editions Of USA TODAY analysis
Sign-up for Amanda Knox Opens Up In Exclusive Interview In Today's Editions Of USA TODAY investment picks
2013/4/16
Amara Mining Considering Several Joint Venture Approaches
ZURICH --
View more Amara Mining Considering Several Joint Venture Approaches analysis
Sign-up for Amara Mining Considering Several Joint Venture Approaches investment picks
2013/5/13
Amara Mining PLC: Posting of Annual Report & Notice of AGM
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1016561&ProfileId=051205&sourceType=1 LONDON --
View more Amara Mining PLC: Posting of Annual Report & Notice of AGM analysis
Sign-up for Amara Mining PLC: Posting of Annual Report & Notice of AGM investment picks
2013/4/30
Amara Mining plc: Receipt of Permits for Kalsaka/Sega Haul Road
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1012124&ProfileId=051205&sourceType=1 LONDON --
View more Amara Mining plc: Receipt of Permits for Kalsaka/Sega Haul Road analysis
Sign-up for Amara Mining plc: Receipt of Permits for Kalsaka/Sega Haul Road investment picks
2013/5/13
Amara Mining: Posting of Annual Report and Notice of AGM
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1016536&ProfileId=051205&sourceType=1 LONDON --
View more Amara Mining: Posting of Annual Report and Notice of AGM analysis
Sign-up for Amara Mining: Posting of Annual Report and Notice of AGM investment picks
2013/3/5
Amarantus BioScience, Brewer Sports International and TCMG Announce #C4CT Concussion Awareness Conference
Amarantus BioScience , Inc. (OTCQB: AMBS), a biotechnology company discovering and developing treatments and diagnostics for diseases associated with the neurodegeneration and apoptosis centered around its patented therapeutic protein MANF, Brewer Sports International (BSI) and Toi Cook Management Group (TCMG) today announced joint hosting of the Coalition for Concussion Treatment (#C4CT) Concussion Awareness Conference (#C4CT Conference) in Minneapolis on June 19, 2013 at the Minneapolis Club.
View more Amarantus BioScience, Brewer Sports International and TCMG Announce #C4CT Concussion Awareness Conference analysis
Sign-up for Amarantus BioScience, Brewer Sports International and TCMG Announce #C4CT Concussion Awareness Conference investment picks
2013/4/30
Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
BEDMINSTER, N.J. and DUBLIN, Ireland, April 30, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the approval of the Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for BASF as an additional Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier.
View more Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier analysis
Sign-up for Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier investment picks
2013/4/18
Amarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier
BEDMINSTER, N.J. and DUBLIN, Ireland, April 18, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today the approval of the Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to add Chemport, Inc. as an additional Vascepa® (icosapent ethyl) active pharmaceutical ingredient (API) supplier.
View more Amarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier analysis
Sign-up for Amarin Announces Approval of Supplemental New Drug Application for Chemport as Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier investment picks
2013/4/23
Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia
BEDMINSTER, N.J. and DUBLIN, Ireland, April 23, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Food and Drug Administration (FDA) has accepted its Supplemental New Drug Application (sNDA) seeking approval for the marketing and sale of Vascepa (R) (icosapent ethyl) capsules for use as an adjunct to diet in the treatment of adult patients with high triglycerides (TG ≥200 mg/dL and <500 mg/dL) with mixed dyslipidemia.
View more Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia analysis
Sign-up for Amarin Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides (>200 mg/dL and <500 mg/dL) With Mixed Dyslipidemia investment picks
2013/4/8
Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R)
BEDMINSTER, N.J., and DUBLIN, Ireland, April 8, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today additional data from Amarin's previously announced MARINE and ANCHOR Phase 3 clinical trial results of Vascepa ® (icosapent ethyl) related to the effect of Vascepa on apolipoprotein C-III (Apo C-III). The lipoprotein Apo C-III is thought to inhibit the clearance of triglycerides from the blood.
View more Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R) analysis
Sign-up for Amarin Announces New Clinical Data Showing Significant Reductions in Apolipoprotein C-III Levels in MARINE and ANCHOR Studies of Vascepa(R) investment picks
2013/3/7
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, March 7, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 13/614,111titled "Stable Pharmaceutical Compositions and Methods of Using the Same." This application includes claims intended to protect the proposed Vascepa ® (icosapent ethyl) indication based on Amarin's Phase 3 ANCHOR clinical trial results.
View more Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication analysis
Sign-up for Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,111 Related to Vascepa(R) and Planned ANCHOR Indication investment picks
2013/2/12
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb.
View more Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication analysis
Sign-up for Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,129 Related to Vascepa(R) and FDA Approved MARINE Indication investment picks
2013/2/7
Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb.
View more Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication analysis
Sign-up for Amarin Announces Notification of Patent Allowance for U.S. Application 13/614,146 Related to Vascepa(R) and FDA Approved MARINE Indication investment picks
2013/1/31
Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan.
View more Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication analysis
Sign-up for Amarin Announces Notification of Two Additional Patent Allowances for U.S. Applications (13/458,496 and 13/349,157) Related to Vascepa(R) and FDA Approved MARINE Indication investment picks
2013/2/26
Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb.
View more Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia analysis
Sign-up for Amarin Announces Submission of Supplemental New Drug Application (sNDA) for Vascepa(R) for the Treatment of Patients With High Triglycerides With Mixed Dyslipidemia investment picks
2013/2/28
Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations
BEDMINSTER, N.J. and DUBLIN, Ireland, Feb.
View more Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations analysis
Sign-up for Amarin Reports Fourth Quarter and Year-End 2012 Financial Results and Provides Update on Operations investment picks
2013/4/23
Amarin Says FDA Accepts Supplemental New Drug Application for Vascepa
Amarin Corp.
View more Amarin Says FDA Accepts Supplemental New Drug Application for Vascepa analysis
Sign-up for Amarin Says FDA Accepts Supplemental New Drug Application for Vascepa investment picks
2013/2/21
Amarin to Present at the CITI 2013 Global Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb.
View more Amarin to Present at the CITI 2013 Global Healthcare Conference analysis
Sign-up for Amarin to Present at the CITI 2013 Global Healthcare Conference investment picks
2013/2/7
Amarin to Present at the Leerink Swann Global Healthcare Conference 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Feb.
View more Amarin to Present at the Leerink Swann Global Healthcare Conference 2013 analysis
Sign-up for Amarin to Present at the Leerink Swann Global Healthcare Conference 2013 investment picks
2013/5/3
Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013
BEDMINSTER, N.J. and DUBLIN, May 3, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN) , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's first quarter 2013 financial results and provide an operational update on Thursday, May 9, 2013, at 4:30 p.m. EDT.
View more Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013 analysis
Sign-up for Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
Articles From: Alvarion® Chosen to Deploy Smart City Solution in Mar del Plata, Argentina for Better Governance, Efficiency of Services and Quality of Life to Amarin to Report First Quarter 2013 Results and Host Conference Call on May 9, 2013
Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Mutual Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title
ETFs by:
Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name
Investment Categories by:
Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry
Premimum Stocks by:
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry
Premimum Funds by:
Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title
Premimum ETFs by:
Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name
Popular Articles by:
Title |  Date |  Author |  Collection |  Popularity |  Interest
SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Popular SEC Filings by:
Title |  Date |  Company |  Symbol |  Interest |  Popularity
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.